Abstract 127P
Background
Although tumor budding (TB) has been recognized as a representative adverse prognosticator in gastrointestinal malignancies, it is not well elucidated in distal-extrahepatic bile duct carcinoma (DBDC).
Methods
Herein, we investigated the prognostic significance of peritumoral (PTB) and intratumoral (ITB) budding according to the modified DBDC staging of the 8th edition of the American Joint Committee on Cancer. PTB and ITB were independently evaluated in a cohort of DBDC patients (n=410) based on the 2016 International Tumor Budding Consensus Conference (ITBCC).
Results
High levels of PTB (PTBHigh, ≥ grade 2) and ITB (ITBHigh, ≥ grade 3) were identified in 316 (77%) and 238 (58%) cases, respectively. In univariate analysis, PTBHigh and ITBHigh (both P=0.001); larger size and sclerosing tumor growth pattern (both P<0.001); higher histologic grade (P=0.006); extrapancreatic location (P=0.015); adenocarcinomas unrelated to intraductal papillary neoplasm of the bile duct (IPNB) (P=0.008); pancreatic, duodenal, and lymphovascular invasion (all P<0.001); perineural invasion (P=0.003); cancer involvement of the bile duct resection margin, nodal metastasis, and higher T and N categories and disease stages (all P<0.001) were associated with shorter patient overall survival (OS) times. In multivariate analysis, PTBHigh and ITBHigh remained poor independent prognostic indicators of OS in DBDC patients. Specifically, ITBHigh could predict poor prognosis (P=0.025) in patients with stage I (T1N0) DBDC.
Conclusions
Both PTBHigh and ITBHigh were strong prognostic indicators in patients with DBDC. Thus, ITB could be used to predict worse prognoses in patients with DBDC, in which PTB is difficult to assess, especially for patients with stage I (T1N0) DBDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17